Dyskinesias assessment in Phase II studies.
Damier
P
P
Centre d'Investigation Clinique-INSERM U 289, Paris, France.
Jaillon
C
C
Clavier
I
I
Arnulf
I
I
Bonnet
A M
AM
Bejjani
B P
BP
Agid
Y
Y
D001692:Biological Transport / Q000502:physiology; D001921:Brain / Q000378:metabolism; D002985:Clinical Protocols; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis* / Q000209:etiology*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity
D018491:Dopamine Agonists; D007980:Levodopa; D004298:Dopamine